The NCMAG Council makes decisions on the proposed use of cancer medicines.
These medicines uses are planned for review by NCMAG:
NCMAG119 – Pomalidomide in combination with dexamethasone
For treatment of adult patients with multiple myeloma who have received at least one prior treatment regimen including lenalidomide (off-label use and pending off-patent status)
- Council meeting date: 12 December 2024
- Planned publication date: 16 January 2025
NCMAG120 – Pomalidomide in combination with bortezomib and dexamethasone
For treatment of adult patients with multiple myeloma who have received at least one prior treatment regimen including lenalidomide (off-patent)
- Council meeting date: 12 December 2024
- Planned publication date: 16 January 2025
NCMAG121 – Nivolumab in combination with Ipilimumab
For neoadjuvant treatment of resectable stage 3 melanoma (off-label use)
- Council meeting date: 20 March 2025
- Planned publication date: 24 April 2025
NCMAG122 – Pembrolizumab
For neoadjuvant treatment of stage 3B to 3D or oligometastatic resectable stage 4 melanoma (off-label use)
- Council meeting date: 20 March 2025
- Planned publication date: 24 April 2025